Drug intelligence / Profile preview

raxtozinamaran

Development stage: Phase 1
Lead developer: GSK
Modality: mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

Raxtozinamaran (GSK4064095A) is a second-generation messenger RNA (mRNA) vaccine candidate developed by GSK in collaboration with CureVac for the prevention of COVID-19. It consists of a 5-capped, chemically unmodified mRNA sequence that encodes the full-length spike (S) protein of the SARS-CoV-2 virus, encapsulated within lipid nanoparticles (LNPs). The vaccine utilizes an optimized mRNA backbone designed to enhance intracellular stability and translation efficiency, potentially allowing for lower dosing and improved immunogenicity compared to first-generation mRNA vaccines. Raxtozinamaran is part of a broader strategic collaboration between GSK and CureVac to develop mRNA-based vaccines for various infectious diseases, including respiratory syncytial virus (RSV) and influenza, leveraging a shared technology platform.

Other names: raxtozinamaran

Targets

SARS-CoV-2 spike

Beyond the preview

Go deeper on raxtozinamaran.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on raxtozinamaran.

Explore the full profile